A glance over the cannabinoid machinery to design new anti-angiogenic compounds

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 590-595

  De Filippis, D ^a   Iuvone, T ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Angiogenesis; Cancer; Cannabinoids; Cannabis; CB receptors; Inflammation; Palmitoylthanolamide

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADELMIDROL; ANANDAMIDE; ANGIOGENESIS INHIBITOR; BORRELIDIN; CANNABIDIOL; CANNABIDIOL DERIVATIVE; CANNABIGEROL; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL; DRONABINOL; ENDOCANNABINOID; FUMAGILLIN; HU 331; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG; WITHAFERIN A; BIOMIMETIC MATERIAL;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; DISEASE ASSOCIATION; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; GRANULOMA; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SKIN DISEASE; ANIMAL; BIOSYNTHESIS; CHEMISTRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; ANIMALS; BIOMIMETIC MATERIALS; CANNABINOIDS; DRUG DESIGN; ENDOCANNABINOIDS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 67649892036     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788167637     Document Type: Review

References (50)

1. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86, 353-64.
2. Jain, R. K. Clearing the smoke on nicotine and angiogenesis. Nat. Med., 2001, 7, 775-7.
3. Blau, H.M.; Banfi, A. The well-tempered vessel. Nat. Med., 2001, 7, 532-4.
4. Griffioen, A.W.; Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev., 2000, 52, 237-68.
5. Ellis, L.M.; Hicklin, D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer, 2008, 8, 579-91.
6. Aljada, A.; O'Connor, L.; Fu, Y.Y.; Mousa, S.A. PPARgamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis, 2008, 11, 361-7.
7. Grummer, M.A.; Sullivan, J.A.; Magness, R.R.; Bird, I.M. VEGF acts through novel, pregnancy-enhanced receptor signaling pathways to stimulate eNOS activity in uterine artery endothelial cells. Biochem. J., 2009, 417, 501-11.
8. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-57.
9. Raffetto, J.D.; Khalil, R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol., 2008, 75, 346-59.
10. De Filippis, D.; Russo, A.; D'Amico, A.; Esposito, G.; Pietropaolo, C.; Cinelli, M.; Russo, G.; Iuvone, T. Cannabinoids reduce granuloma-associated angiogenesis in rats by controlling transcription and expression of mast cell protease-5. Br. J. Pharmacol., 2008, 154, 1672-9.
11. De Filippis, D.; D'Amico, A.; Cinelli, M.P.; Esposito, G.; Di Marzo, V.; Iuvone, T. Adelmidrol, a palmitoylethanolamide analog, reduces chronic inflammation in a carrageenin-granuloma model in rats. J. Cell. Mol. Med., 2008, Epub ahead of print]
12. Russo, A.; Russo, G.; Peticca, M.; Pietropaolo, C.; Di Rosa, M.; Iuvone, T. Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5. Br. J. Pharmacol., 2005, 145, 24-33
13. Caughey, G,H. Mast cell tryptases and chymases in inflammation and host defense. Immunol. Rev., 2007, 217, 141-54.
14. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature, 2005, 438, 967-74.
15. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature, 2005, 438, 932-36.
16. Gariano, R.F.; Gardner, T.W. Retinal angiogenesis in development and disease. Nature, 2005, 438, 960-66.
17. Tinelli, A.; Martignago, R.; Vergara, D.; Leo, G.; Malvasi, A.; Tinelli, R. Endometriosis management: workflow on genomics and proteomics and future biomolecular pharmacotherapy. Curr. Med. Chem., 2008, 15, 2099-107.
18. Elsohly, M.A.; Slade, D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci., 2005, 78, 539-48.
19. Vree, T.B.; Breimer, D.D.; Van Ginneken, C.A.M.; Van Rossum, J.M. Identification in hashish of tetrahydrocannabinol, cannabidiol, and cannabinol analogs with a methyl side-chain. J. Pharm. Pharmacol., 1972, 24, 7-12
20. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
21. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the CBreceptor. Science, 1992, 258, 1946-49.
22. Howlett, A.C.; Champion-Dorow, T.M.; McMahon, L.L.; Westlake, T.M. The CBreceptor: biochemical and cellular properties in neuroblastoma cells. Pharmacol. Biochem. Behav., 1991, 40, 565-69.
23. Huffman, J.W. The search for selective ligands for the CB2 receptor. Curr. Pharm. Des., 2000, 6, 1323-37.
24. Lin, S.; Khanolkar, A.D.; Fan, P.; Goutopoulos, A.; Qin, C.; Papahadjis, D.; Makriyannis, A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 CBreceptors and metabolic stability. J. Med. Chem., 1998, 41, 5353-61.
25. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to CBreceptors. Biochem. Pharmacol., 1995, 50, 83-90.
26. Stella, N.; Schweitzer, P.; Piomelli, D. A second endogenous CB that modulates long-term potentiation. Nature, 1997, 388, 773-8.
27. Lambert, D.M.; Vandevoorde, S.; Jonsson, K.O.; Fowler, C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Curr. Med. Chem., 2002, 9, 663-74.
28. Thakur, G.A.; Duclos, R.I.; Makriyannis, A. Natural cannabinoids: templates for drug discovery. Life Sci., 2005, 78, 454-66.
29. Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin B.R.; Mechoulam, R.; Pertwee, R.G. International Union of Pharmacology. XXVII. classification of cbreceptors. Pharmacol. Rev., 2002, 54, 161-202.
30. Khanolkar, A.D.; Palmer, S.L.; Makriyannis, A. Molecular probes for the CBreceptors. Chem. Phys. Lipids, 2000, 108, 37-52.
31. O'Sullivan, S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol., 2007, 152, 576-82.
32. Rohmer, M. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. Nat. Prod. Rep., 1999, 16, 565- 574.
33. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J.C.; Piomelli, D. Formation and inactivation of endogenous CBanandamide in central neurons. Nature, 1994, 372, 686-91.
34. Okamoto, Y.; Morishita, J.; Tsuboi, K.; Tonai, T.; Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem., 2004, 279, 5298-305.
35. Ueda, N.; Okamoto, Y.; Morishita, J. N-Acylphosphatidylethanolamine hydrolyzing phospholipase D: a novel enzyme of the B-lactamase fold family releasing anandamide and other N-acylethanolamines. Life Sci., 2005, 77, 1750-58.
36. Sun, Y.X.; Tsuboi, K.; Okamoto, Y.; Tonai, T.; Murakami, M.; Kudo, I.; Ueda, N. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J., 2004, 380, 749-756.
37. Jhaveri, M.D.; Richardson, D.; Robinson, I.; Garle, M.J.; Patel, A.; Sun, Y.; Sagar, D.R.; Bennett, A.J.; Alexander, S.P.; Kendall, D.A.; Barrett, D.A.; Chapman, V. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endoCB-related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology, 2008, 55, 85-93.
38. Kogan, N.M.; Mechoulam, R. Cannabinoids in health and disease. Dialogues Clin. Neurosci., 2007, 9, 413-30.
39. Di Marzo, V. Targeting the endoCBsystem: to enhance or reduce? Nat. Rev. Drug. Discov., 2008, 7, 438-55.
40. Casanova, M.L.; Blázquez, C.; Martínez-Palacio, J.; Villanueva, C.; Fernández-Aceñero, M.J.; Huffman, J.W.; Jorcano, J.L.; Guzmán, M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of CBreceptors. J. Clin. Invest., 2003, 111, 43-50.
41. Blázquez, C.; Casanova, M.L.; Planas, A.; G-acomez Del Pulgar, T.; Villanueva, C.; Fernández-Aceñero, M.J.; Aragonés, J.; Huffman, J.W.; Jorcano, J.L.; Guzmán, M. Inhibition of tumor angiogenesis by cannabinoids. FASEB J., 2003, 17, 529-31.
42. Blázquez, C.; González-Feria, L.; Alvarez, L.; Haro, A.; Casanova, M.L.; Guzmán, M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer. Res., 2004, 64, 5617-23.
43. Maccarrone, M.; Bari, M.; Lorenzon, T. Bisogno, T.; Di Marzo, V.; Finazzi-Agrò, A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J. Biol. Chem., 2000, 275,13484-92.
44. Portella. G.; Laezza, C.; Laccetti, P.; De Petrocellis, L.; Di Marzo, V.; Bifulco, M. Inhibitory effects of CBCB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J., 2003, 17, 1771-3.
45. Kogan, N.M.; Blázquez, C.; Alvarez, L.; Gallily, R.; Schlesinger, M.; Guzmán, M.; Mechoulam, R. A annabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol. Pharmacol., 2006, 70, 51-9.
46. Járai, Z.; Wagner, J.A.; Varga, K.; Lake, K.D.; Compton, D.R.; Martin, B.R.; Zimmer, A.M.; Bonner, T.I.; Buckley, N.E.; Mezey, E.; Razdan, R.K.; Zimmer, A.; Kunos, G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U S A., 1999, 96, 14136-41.
47. Golech, S.A.; McCarron, R.M.; Chen, Y.; Bembry, J.; Lenz, F.; Mechoulam, R.; Shohami, E.; Spatz, M. Human brain endothelium: coexpression and function of vanilloid and endoCBreceptors. Brain. Res. Mol. Brain. Res., 2004, 132, 87-92.
48. Wagner, J.A.; Varga, K.; Ellis, E.F.; Rzigalinski, B.A.; Martin, B.R.; Kunos, G. Activation of peripheral CB1 CBreceptors in haemorrhagic shock. Nature, 1997, 390, 518-21.
49. Guzmán, M.; Duarte, M.J.; Blázquez, C.; Ravina, J.; Rosa, M.C.; Galve-Roperh, I.; Sánchez, C.; Velasco, G.; González-Feria, L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer, 2006, 95,197-203
50. De Filippis, D.; Russo, A.; De Stefano, D.; Maiuri, M.C.; Esposito, G; Cinelli, M.P.; Pietropaolo, C.; Carnuccio, R.; Russo, G.; Iuvone, T. Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. J. Mol. Med., 2007, 85, 635-45.